NYSE: MRSHMarsh & Mclennan Companies Inc Stock
$186.74+1.45 (+0.78%)
Updated Feb 27, 2026
MRSH Price
$186.74
Fair Value Price
N/A
Market Cap
$90.41B
52 Week Low
$170.37
52 Week High
$248.00
P/E
22.02x
P/B
5.99x
P/S
3.38x
PEG
1.57x
Dividend Yield
1.88%
Revenue
$26.98B
Earnings
$4.16B
Gross Margin
100%
Operating Margin
23.81%
Profit Margin
15.4%
Debt to Equity
2.87
Operating Cash Flow
$5B
Beta
0.63
Next Earnings
Apr 16, 2026
Ex-Dividend
Apr 9, 2026
Next Dividend
May 15, 2026
MRSH Overview
Marsh & McLennan Companies, Incorporated offers insurance brokerage, reinsurance, and other risk management services, as well as health, wealth, career consulting, and economic and brand consulting services and products. Its four main operating companies are Marsh, Guy Carpenter, Mercer, and Oliver Wyman. Marsh & McLennan Companies was founded in 1871 and is headquartered in New York, NY.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine MRSH's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important MRSH news, forecast changes, insider trades & much more!
MRSH News
Overview
Due Diligence Score
–
Industry Average (33)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MRSH scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MRSH ($186.74) is trading above its intrinsic value of $94.81, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
MRSH is good value based on its earnings relative to its share price (22.02x), compared to the US market average (37.98x)
P/E vs Market Valuation
MRSH is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more MRSH due diligence checks available for Premium users.
Valuation
MRSH price to earnings (PE)
For valuing profitable companies with steady earnings
Company
22.02x
Industry
22.58x
Market
37.98x
MRSH is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
MRSH is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
MRSH price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.99x
Industry
4.05x
MRSH is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MRSH price to earnings growth (PEG)
For valuing profitable companies with growth potential
MRSH is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
MRSH's financial health
Profit margin
Revenue
$6.6B
Net Income
$821.0M
Profit Margin
12.4%
MRSH's Earnings (EBIT) of $6.43B... subscribe to Premium to read more.
Interest Coverage Financials
MRSH's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$58.7B
Liabilities
$43.4B
Debt to equity
2.87
MRSH's short-term assets ($23.20B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MRSH's short-term assets ($23.20B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MRSH's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
MRSH's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$2.2B
Investing
-$523.0M
Financing
-$2.0B
MRSH's operating cash flow ($5.29B)... subscribe to Premium to read more.
Debt Coverage Financials
MRSH vs Insurance Stocks
Marsh & Mclennan Companies Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.